Does the media favor ELDN or FDMT?

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat 4D Molecular Therapeutics' score of 0.55 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GERN or ELDN?

In the previous week, Geron and Geron both had 1 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Geron's score of 1.54 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, ELDN or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A Design Therapeutics N/A N/A -$69.79M -$1.18 N/A

Is ELDN or DSGN more profitable?

Design Therapeutics' return on equity of -34.03% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% Design Therapeutics N/A -34.03% -32.05%

Does the media favor ELDN or DSGN?

In the previous week, Design Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Design Therapeutics and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Design Therapeutics' score of 0.71 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Design Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ANNX or ELDN?

Annexon is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A

Is ANNX or ELDN more profitable?

Annexon's return on equity of -106.15% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media refer more to ANNX or ELDN?

In the previous week, Annexon had 7 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 8 mentions for Annexon and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Annexon's score of 0.83 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, ELDN or SLDB?

Solid Biosciences is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is ELDN or SLDB more profitable?

Solid Biosciences' return on equity of -71.35% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% Solid Biosciences N/A -71.35% -60.58%

Does the media favor ELDN or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Solid Biosciences' score of 0.25 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eledon Pharmaceuticals (ELDN) Competitors

$2.49 +0.06 (+2.47%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.50 +0.01 (+0.40%)

As of 10/2/2026 07:31 PM Eastern

Compare

ELDN vs. FDMT, GERN, DSGN, ANNX, and SLDB

Should you buy Eledon Pharmaceuticals stock or one of its competitors? Eledon Pharmaceuticals's main competitors and comparable companies include 4D Molecular Therapeutics (FDMT), Geron (GERN), Design Therapeutics (DSGN), Annexon (ANNX), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eledon Pharmaceuticals compare to 4D Molecular Therapeutics?

Eledon Pharmaceuticals (NASDAQ:ELDN) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Eledon Pharmaceuticals has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat 4D Molecular Therapeutics' score of 0.55 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 301.61%. 4D Molecular Therapeutics has a consensus price target of $29.00, indicating a potential upside of 112.14%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

Summary

4D Molecular Therapeutics beats Eledon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Geron?

Geron (NASDAQ:GERN) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

73.7% of Geron shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Geron currently has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Eledon Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 301.61%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Eledon Pharmaceuticals has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$204.56M	3.77	-$83.50M	-$0.11	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

In the previous week, Geron and Geron both had 1 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Geron's score of 1.54 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Eledon Pharmaceuticals beats Geron on 8 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Design Therapeutics?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Design Therapeutics (NASDAQ:DSGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, Design Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Design Therapeutics and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Design Therapeutics' score of 0.71 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Design Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Eledon Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 301.61%. Design Therapeutics has a consensus target price of $17.86, suggesting a potential upside of 44.71%. Given Eledon Pharmaceuticals' higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Design Therapeutics' return on equity of -34.03% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Design Therapeutics	N/A	-34.03%	-32.05%

Summary

Design Therapeutics beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Annexon?

Annexon (NASDAQ:ANNX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Annexon is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Annexon's return on equity of -106.15% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Annexon presently has a consensus price target of $15.29, indicating a potential upside of 264.81%. Eledon Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 301.61%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Annexon has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

In the previous week, Annexon had 7 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 8 mentions for Annexon and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Annexon's score of 0.83 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Eledon Pharmaceuticals beats Annexon on 7 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Solid Biosciences?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Solid Biosciences' return on equity of -71.35% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Solid Biosciences	N/A	-71.35%	-60.58%

Eledon Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 301.61%. Solid Biosciences has a consensus price target of $18.69, indicating a potential upside of 172.88%. Given Eledon Pharmaceuticals' higher possible upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Solid Biosciences is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

In the previous week, Solid Biosciences had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.76 beat Solid Biosciences' score of 0.25 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market.

Summary

Eledon Pharmaceuticals beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$202.34M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-2.74	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.84	16.63	10.93	6.31
Net Income	-$45.62M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-6.04%	-2.99%	-2.00%	-1.66%
1 Month Performance	-17.55%	-10.81%	-6.19%	-4.68%
1 Year Performance	-12.32%	19.19%	8.03%	1.57%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	1.9135 of 5 stars	$2.49 +2.5%	$10.00 +301.6%	-12.3%	$202.34M	N/A	N/A	33	Positive News Gap Up
FDMT 4D Molecular Therapeutics	2.8323 of 5 stars	$14.49 -0.5%	$29.00 +100.1%	+59.9%	$800.43M	$85.21M	N/A	196	Analyst Forecast Gap Up
GERN Geron	2.2012 of 5 stars	$1.24 -0.8%	$4.00 +222.6%	-11.1%	$796.66M	$183.88M	N/A	258
DSGN Design Therapeutics	2.7472 of 5 stars	$12.62 +2.1%	$16.50 +30.7%	+102.0%	$789.76M	N/A	N/A	55	News Coverage Positive News Analyst Upgrade
ANNX Annexon	3.5959 of 5 stars	$4.13 +3.0%	$15.14 +266.7%	+31.3%	$782.97M	N/A	N/A	92	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. FDMT, GERN, DSGN, ANNX, and SLDB

How does Eledon Pharmaceuticals compare to 4D Molecular Therapeutics?

Summary

How does Eledon Pharmaceuticals compare to Geron?

Summary

How does Eledon Pharmaceuticals compare to Design Therapeutics?

Summary

How does Eledon Pharmaceuticals compare to Annexon?

Summary

How does Eledon Pharmaceuticals compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. FDMT, GERN, DSGN, ANNX, and SLDB

How does Eledon Pharmaceuticals compare to 4D Molecular Therapeutics?

Which has stronger valuation and earnings, ELDN or FDMT?

Does the media favor ELDN or FDMT?

Which has more volatility & risk, ELDN or FDMT?

Do analysts prefer ELDN or FDMT?

Do insiders and institutionals believe in ELDN or FDMT?

Is ELDN or FDMT more profitable?

Summary

How does Eledon Pharmaceuticals compare to Geron?

Is GERN or ELDN more profitable?

Which has more risk & volatility, GERN or ELDN?

Do insiders & institutionals have more ownership in GERN or ELDN?

Do analysts prefer GERN or ELDN?

Which has stronger earnings and valuation, GERN or ELDN?

Does the media prefer GERN or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Design Therapeutics?

Does the media favor ELDN or DSGN?

Which has preferable earnings & valuation, ELDN or DSGN?

Which has more volatility & risk, ELDN or DSGN?

Do insiders and institutionals hold more shares of ELDN or DSGN?

Do analysts prefer ELDN or DSGN?

Is ELDN or DSGN more profitable?

Summary

How does Eledon Pharmaceuticals compare to Annexon?

Which has better earnings and valuation, ANNX or ELDN?

Do insiders & institutionals believe in ANNX or ELDN?

Is ANNX or ELDN more profitable?

Do analysts recommend ANNX or ELDN?

Which has more risk & volatility, ANNX or ELDN?

Does the media refer more to ANNX or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Solid Biosciences?

Is ELDN or SLDB more profitable?

Do analysts recommend ELDN or SLDB?

Do insiders and institutionals believe in ELDN or SLDB?

Which has better earnings and valuation, ELDN or SLDB?

Does the media favor ELDN or SLDB?

Which has more risk and volatility, ELDN or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools